Eli Lilly, EMS, Takeda and ST Pharm are in line for exits after muscle disease therapy developer Avidity filed for a $100m initial public offering.
US-based biopharmaceutical developer Avidity Biosciences has filed to raise up to $100m in an initial public offering that will enable pharmaceutical firms Eli Lilly, EMS and Takeda to exit.
Avidity is working on antibody oligonucleotide conjugates – a type of biomolecule that hypothetically combines precision and tissue selectivity – to treat serious diseases.
The company is initially concentrating on muscle diseases and will spend part of the IPO proceeds on advancing its lead drug candidate, AOC 1001, through a…
